Literature DB >> 10065327

Adenosine and preconditioning revisited.

T Miura1, A Tsuchida.   

Abstract

1. Myocardial tolerance against infarction is substantially increased by exposing myocytes to 3-10 min transient ischaemia. In this phenomenon, termed 'preconditioning', the adenosine receptor is one of the redundant triggers and the best characterized factor in the cardioprotective mechanism. 2. An increase in interstitial adenosine during preconditioning is thought to be derived primarily from hydrolysis of 5'-AMP in the myocyte by cytosolic 5'-nucleotidase, although a contribution of ectosolic 5'-nucleotidase remains controversial. Adenosine production during ischaemia is substantially suppressed in the preconditioned myocardium, probably due to a decrease in ATP utilization. 3. The adenosine receptor needs to be activated not only at the time of preconditioning ischemia, but also during ischaemic insult for the preconditioning to be cardioprotective. However, the extent of cardioprotection afforded by preconditioning is primarily determined by the interstitial adenosine level achieved during preconditioning ischaemia, not by the level during sustained ischaemia. These data suggest that a post-receptor mechanism downstream of the adenosine receptor may be up-regulated after preconditioning. 4. Studies in vitro suggest that the subtypes of adenosine receptor relevant to preconditioning against infarction are A1 and A3, the activation of which appears to provide additive protection. The functional interrelationship between these subtypes in vivo remains unknown. 5. An important step downstream of adenosine receptor activation is protein kinase C (PKC), which facilitates opening of ATP-sensitive potassium (KATP) channels, probably leading to enhancement of myocardial tolerance. However, activation of other protein kinases, such as tyrosine kinase, may also be important in preconditioning, depending on the animal species and preconditioning protocols. The PKC isoform and location of KATP channels (i.e. sarcolemmal vs mitochondrial KATP) that induce anti-infarct tolerance in myocytes remain to be identified.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065327     DOI: 10.1046/j.1440-1681.1999.03003.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  3 in total

1.  Uridine-5'-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct.

Authors:  Smadar Yitzhaki; Asher Shainberg; Yelena Cheporko; Bernardo A Vidne; Alex Sagie; Kenneth A Jacobson; Edith Hochhauser
Journal:  Biochem Pharmacol       Date:  2006-08-30       Impact factor: 5.858

2.  Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning.

Authors:  M Gonzalez-Zulueta; A B Feldman; L J Klesse; R G Kalb; J F Dillman; L F Parada; T M Dawson; V L Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  P2Y2 receptor agonist with enhanced stability protects the heart from ischemic damage in vitro and in vivo.

Authors:  Edith Hochhauser; Ronit Cohen; Maayan Waldman; Anna Maksin; Ahuva Isak; Dan Aravot; P Suresh Jayasekara; Christa E Müller; Kenneth A Jacobson; Asher Shainberg
Journal:  Purinergic Signal       Date:  2013-07-05       Impact factor: 3.765

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.